Bipartisan Legislation Introduced to Increase Access to Biosimilars in Medicare Plans

Goodwin
Contact

Goodwin

On April 26, Representatives Paul D. Tonko (D-NY) and Bob Gibbs (R-OH) introduced the Star Rating for Biosimilars Act.  The proposed legislation would direct the U.S. Department of Health & Human Services (HHS) to evaluate Medicare plans based on whether or not cost-saving biosimilars are available to enrollees and to evaluate Medicare Advantage and Part D plans on access to biosimilar drugs.  The proposed legislation is designed to help motivate Medicare plans to improve performance and access to biosimilars.  In a press release Representative Tonko said: “My bill shines a spotlight on existing barriers in current health plans, provides meaningful transparency where plans fall short, and allows for reform to unlock the billions in savings for patients and taxpayers. No family should have to choose between paying their prescription or putting food on the table. It’s past time Congress act to make these lifesaving treatments more accessible to all.”

The Star Rating for Biosimilars Act has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means for consideration.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.